Weekend Avenger: Welcome to Friday, dear readers, and now that the “Endgame” spoiler ban is officially lifted, welcome back to everyone previously dusted by the Thanos Snap. You’ve survived…
By GREGORY ZELLER // Add another critical Brazilian regulatory approval to Chembio Diagnostics’ portfolio. The Medford-based point-of-care diagnostics specialist announced this its week the Agência Nacional de Vigilância Sanitária, Brazil’s…
Welcome to Wednesday: Over the hump of another busy workweek, dear friends. We are the world: To our readers in the 193 sovereign states comprising the U.N. General Assembly,…
Hump-hopping: Welcome to Wednesday, dear readers, as we speed through another exciting (and mercilessly damp) week of socioeconomic innovation. It’s Aug. 15 out there, and today we observe the 73rd…
Chembio Diagnostics has been approved to sell its combination test for HIV and syphilis in most of Europe and the Caribbean. The single-use test kits offer rapid detection of antibodies…
The national health-regulatory agency of Brazil has approved commercial use of Chembio Diagnostics’ rapid field rest for the Zika virus – a major step toward selling the product in the…
By GREGORY ZELLER // With declining Latin American sales contributing to a revenues losing streak, Chembio Diagnostics has shaken up its international rotation. The Medford-based biotech, which manufactures rapid point-of-care…
Medford-based Chembio Diagnostics has won a $13.2 million federal contract to further develop its rapid test for the Zika virus, the company announced Thursday. Almost $6 million of the money –…
By GREGORY ZELLER // An oversupplied Latin American market put a dent in Chembio Diagnostic’s 2015 earnings, but coming battles with the Zika virus may turn fortunes around. That was…
Chembio Diagnostics has been awarded a $550,000 “catalyst grant” to develop a rapid test for the Zika virus and similar maladies. The grant comes from Microsoft co-founder Paul G. Allen,…
Medford-based Chembio Diagnostics has been awarded a $2.1 million grant from Microsoft co-founder Paul G. Allen to develop a speedier test for fevers, including Ebola and malaria. The one-year grant, from…